![ANZUP Cancer, ANZUP](https://anzup.org.au/wp-content/uploads/2024/03/The-SUB-urothelial-DUrvalumab-InjEction-1-SUBDUE-1-trial.png)
![ANZUP Cancer, ANZUP](https://anzup.org.au/wp-content/uploads/2024/03/The-SUB-urothelial-DUrvalumab-InjEction-1-SUBDUE-1-trial.png)
The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer
To assess the safety of sub-urothelial injection of durvalumab and examine the impact on tissue and circulating immune cell populations.